Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_2
3
75%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

NCT01700270
completedphase_2

Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma

NCT01524692
completedphase_2

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

NCT01831726
completedphase_2

Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib

NCT01478373

Clinical Trials (4)

Showing 4 of 4 trials
NCT01700270Phase 1

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

Completed
NCT01524692Phase 2

Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma

Completed
NCT01831726Phase 2

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Completed
NCT01478373Phase 2

Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4